Shanghai Kehua Bio-engineering Co Ltd.
002022
Overview
Corporate Details
- ISIN(s):
- CNE000001KC9
- LEI:
- Country:
- China
- Address:
- N/A
- Website:
- N/A
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
Automate Your Workflow. Get a real-time feed of all Shanghai Kehua Bio-engineering Co Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Shanghai Kehua Bio-engineering Co Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Shanghai Kehua Bio-engineering Co Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea
234080
South Korea
234080
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
South Korea
067290
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
United States of America
MENS
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
Japan
4556
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
Japan
4521
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
United States of America
KALA
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
United States of America
KLRS
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
United States of America
KALV
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
Israel
KMDA